Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, gemcitabine, and
carboplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)
may kill more tumor cells. It is not yet known whether giving pemetrexed disodium with
gemcitabine is more effective than giving pemetrexed disodium with carboplatin in treating
malignant pleural mesothelioma.
PURPOSE: This randomized phase II trial is studying pemetrexed disodium with gemcitabine and
pemetrexed disodium with carboplatin to see how well the combinations work compared to
historical controls in treating patients with advanced malignant pleural mesothelioma.
Phase:
Phase 2
Details
Lead Sponsor:
Eastern Cooperative Oncology Group
Collaborators:
National Cancer Institute (NCI) North Central Cancer Treatment Group